Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800355 | 0.83 | CNR2 (0.44) | MMP8MRGPRX4NPC1BRD4PTGER1 | |
| SCHEMBL20483556 | 0.81 | APP (0.52) | ALDH1A1POLBMAPTTHRBNPC1 | |
| SCHEMBL3798817 | 0.79 | FFAR4 (0.48) | MRGPRX4APPLMNAFFAR4KDM4E | |
| SCHEMBL1492859 | 0.77 | MMP8 (0.65) | MMP8ALDH1A1RECQLPOLBMAPT | |
| SCHEMBL15669148 | 0.77 | L3MBTL1 (0.56) | MMP8ALDH1A1RECQLMAPTLMNA | |
| SCHEMBL13221551 | 0.75 | ALDH1A1 (0.42) | MMP8ALDH1A1RECQLPOLBMAPT | |
| SCHEMBL3799950 | 0.75 | RXRB (0.49) | MRGPRX4NPC1PTGER1S1PR5FFAR4 | |
| SCHEMBL2301928 | 0.75 | CNR2 (0.40) | MMP8ALDH1A1RECQL | |
| SCHEMBL2305263 | 0.72 | CNR2 (0.40) | MMP8ALDH1A1RECQLKDM4E | |
| SCHEMBL26096078 | 0.72 | MAPT (0.51) | MRGPRX4MAPTNPC1PTGER1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902394-B2 | Calcilytic compounds | GLAXOSMITHKLINE LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100029782-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2120898-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008077009-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029782-A1 | Calcilytic Compounds | CALCR, CALCA, CALCB | MMP8 1080/4885ALDH1A1 3794/4885RECQL 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.